Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats.
K Yamaguchi, Toshitaka Nabeshima, K Ishikawa, S Yoshida, T Kameyama
Neuropharmacology October 1987 DOI: 10.1016/0028-3908(87)90168-7 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal experimental study Peer reviewed |
|---|---|
| Population | Rats, including vehicle-pretreated and reserpine-pretreated groups |
| Interventions | Phencyclidine Ritanserin Pindolol Reserpine Imipramine Mianserin |
| Dose | Phencyclidine 5-7.5 mg/kg (head-weaving), 7.5-12.5 mg/kg (head-twitches), 2.5 mg/kg, 5 mg/kg, 1.25 mg/kg; ritanserin 1 mg/kg; pindolol 20 mg/kg s.c. |
| Measures | head-weaving, head-twitches, 5-HT utilization, [3H]5-HT binding sites, [3H]ketanserin binding sites |
| Topics | Serotonin |
| Key findings | Phencyclidine produced head-weaving at 5-7.5 mg/kg and head-twitches at 7.5-12.5 mg/kg in rats. Ritanserin blocked head-twitches and pindolol blocked head-weaving. Reserpine pretreatment increased serotonin utilization, 5-HT1 and 5-HT2 binding sites, and the intensity of phencyclidine-induced head-weaving and head-twitching. The authors propose that phencyclidine induces head-weaving via 5-HT1 receptors, indirectly after serotonin release, and head-twitch via 5-HT2 receptors, directly or indirectly. |
Abstract
Phencyclidine mainly produced head-weaving and head-twitches at doses of 5-7.5 mg/kg and of 7.5-12.5 mg/kg, respectively. Phencyclidine-induced head-twitches and head-weaving were blocked by pretreatment with ritanserin (1 mg/kg), a selective serotonin (5-HT)2 receptor antagonist and with pindolol (20 mg/kg, s.c.), a 5-HT1 receptor antagonist, respectively. In reserpine-pretreated rats, the degree of utilization of 5-HT and the number of 5-HT1 ([3H]5-HT) and 5-HT2 ([3H]ketanserin) binding sites were significantly increased compared with the figures for the vehicle-pretreated rats. The intensity of phencyclidine-induced head-weaving (at the dose of 2.5 mg/kg) and head-twitch (at the doses of 2.5 and 5 mg/kg) was significantly increased in reserpine-pretreated rats compared with that of vehicle-pretreated rats. Furthermore, in the reserpine-pretreated rats, the intensity of phencyclidine (1.25 mg/kg)-induced head-weaving and head-twitches was increased in combination with imipramine, while the intensity of phencyclidine (2.5 mg/kg)-induced head-weaving and head-twitch was decreased by pretreatment with mianserin, a non-selective 5-HT receptor antagonist. These results indicate that phencyclidine induced head-weaving by interacting with 5-HT1 receptors, indirectly after the release of 5-HT and/or with some other mechanisms and induced head-twitch by interacting with 5-HT2 receptors directly and/or indirectly.
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |
Citations in the library
Cited by 8
- Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines Neuropharmacology December 15, 2022
- Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology November 2018
- Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research July 15, 2014
- Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing. European Neuropsychopharmacology March 2011
- Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neuroscience and biobehavioral reviews June 2002
and 3 more in the library
Cites 9
- Lysergic Acid Diethylamide: Sensitive Neuronal Units in the Midbrain Raphe Science August 16, 1968
- Evidence for a central 5‐hydroxytryptamine receptor stimulation by lysergic acid diethylamide British Journal of Pharmacology September 1, 1968
- Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by l‐tryptophan or 5‐methoxy‐N,N‐dimethyltryptamine in rats treated with a monoamine oxidase inhibitor British Journal of Pharmacology December 1, 1971
- Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat European Journal of Pharmacology October 1, 1985
- A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists. British Journal of Pharmacology July 1, 1981
and 4 more in the library